Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Ion Beam Applications wins major German order for 'Be Efficient' sterilization solution
Ion Beam Applications has secured an order in Germany for its 'Be Efficient' electron‑beam sterilization solution; the customer was not disclosed. The order has a list price of about €11–18 million depending on configuration and is intended to deliver high throughput, operational efficiency and lower operating costs. IBA sees long‑term growth opportunities in the business unit, particularly in the context of radiopharmaceutical and environmental applications. » Mere på deraktionaer.de
Ion Beam Applications wins US order for twelve Cyclone cyclotrons
Ion Beam Applications is to deliver twelve Cyclone-KIUBE-PET cyclotrons to a leading US manufacturer; the order value is expected to be at least around €30 million. At the same time, IBA is expanding Actinium-225 production through the PanTera joint venture with SCK CEN, positioning itself centrally in the growing radiopharma value chain. The company is presented as an important supplier for novel theranostic cancer treatments; the stock is described as attractively valued with a P/E ratio of 15. » Mere på deraktionaer.de
Ion Beam Applications: pre-tax profit rises 920% after strong half-year
Ion Beam Applications reports net revenues of €323.7m in the first half (+6%) and a gross margin of 33.7% (+4.2 percentage points). Adjusted EBIT climbed to €17.6m (+66%), while pre-tax profit rose to €12.3m (+920%). The company confirms its 2026 guidance (adjusted EBIT at least €32m) and shows an order backlog of around €1.6bn, about half in high-margin service offerings. In addition, the joint venture Pantera is advancing commercial-scale production of the radioisotope actinium-225 and preparing regulatory filings for clinical trials. » Mere på deraktionaer.de
Ion Beam Applications receives major order for Brazil and remains attractively valued
Ion Beam Applications has received an order for a ProteusONE proton therapy system in Barra da Tijuca, Rio de Janeiro, primarily to treat pediatric patients. The group reports a record order backlog of around €1.6 billion and calculates the end-customer price including maintenance at €35–45 million. The stock recently entered an upward trend; the price-to-earnings ratio (P/E) for the coming year is about 15, so the valuation is still considered attractive. » Mere på deraktionaer.de
Ion Beam Applications receives fourth ProteusONE order in Taiwan
Ion Beam Applications has won another order for a ProteusONE proton therapy system for MacKay Memorial Hospital in Taiwan. The company also secured the quality assurance package from IBA Dosimetry; delivery and installation are planned to enable treatment start in 2029. The order value is expected to be between 35 and 45 million euros and strengthens IBA's market position as well as its visibility in the order books. » Mere på deraktionaer.de
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 323,7 mio. | - |
| Bruttofortjeneste | 108,9 mio. | - |
| Nettoresultat | 9,3 mio. | - |
| EBITDA | 23,9 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 481,69 mio. € |
Antal aktier | 29,16 mio. |
Højeste/laveste i 52 uger | 17,76 € - 9,90 € |
Udbytteafkast | 1,49 % |
Udbytte TTM | 0,25 € |
Beta | 1,23 |
P/E (PE Ratio) | 19,90 |
PEG (PEG Ratio) | 0,41 |
K/I (PB Ratio) | 4,20 |
P/S (PS Ratio) | 0,75 |
Virksomhedsprofil
Ion Beam Applications SA udvikler, fremstiller og understøtter medicinske udstyr og softwareløsninger til kræftbehandling i Belgien, USA og internationalt. Virksomheden opererer gennem segmenterne Protonterapi og andre acceleratorer samt Dosimetri. Segmentet Protonterapi og andre acceleratorer udvikler, fabrikerer og servicerer medicinske og industrielle partikelacceleratorer samt protonterapisystemer. Segmentet tilbyder desuden turnkey-løsninger til behandling af kræft ved brug af protonstråler; og en serie cyklotroner, der anvendes til produktion af radioisotoper til positronemissionstomografi eller SPECT, samt en serie industrielle acceleratorer til sterilisering og ionisering. Segmentet Dosimetri leverer løsninger og services, der øger effektiviteten og minimerer fejl i strålebehandling og i kvalitetssikring og kalibrering af medicinske billeddannelsesprocedurer. Virksomheden har et strategisk forsknings- og udviklingspartnerskab med SCK CEN (Belgisk nuklearforskningscenter) om produktion af Actinium-225 (225Ac), en ny radioisotop til behandling af kræft; og en aftale med University of Pennsylvania om avanceret forskning inden for ConformalFLASH. Ion Beam Applications SA blev stiftet i 1986 og har hovedkontor i Louvain-la-Neuve, Belgien.
| Navn | Ion Beam Applications |
| CEO | Olivier Legrain |
| Hjemsted | Louvain-la-Neuve,
bu Belgien |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsteknologi |
| Børsnotering | 04.01.2000 |
| Medarbejdere | 2.264 |
Tickersymboler
| Børs | Symbol |
|---|---|
Euronext | IBAB.BR |
Pnk | IOBCF |
Brussels Stock Exchange | IBAB.BR |
Frankfurt | IOB.F |
Düsseldorf | IOB.DU |
London | 0GZK.L |
München | IOB.MU |